STOCK TITAN

INHIBITOR THERAPTICS INC - $INTI STOCK NEWS

Welcome to our dedicated page for INHIBITOR THERAPTICS news (Ticker: $INTI), a resource for investors and traders seeking the latest updates and insights on INHIBITOR THERAPTICS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INHIBITOR THERAPTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INHIBITOR THERAPTICS's position in the market.

Rhea-AI Summary
Inhibitor Therapeutics, Inc. (INTI) aims to treat Basal Cell Carcinoma Nevus Syndrome (BCCNS) with Itraconazole. The Scientific Advisory Board (SAB) is reviewing the Phase 2b trial results to assess clinical usefulness prior to submitting the New Drug Application (NDA) to FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Inhibitor Therapeutics, Inc. (INTI) has entered into an exclusive licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930, focusing on the use of Itraconazole as an angiogenesis inhibitor in prostate cancer, basal cell carcinoma, and lung cancer. The License is expected to yield a modest annual royalty rate with milestone payments typical to such a license.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
44.74%
Tags
none
INHIBITOR THERAPTICS INC

OTC:INTI

INTI Rankings

INTI Stock Data

13.33M
75.56M
59.55%
0.23%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Tampa

About INTI

hedgepath pharmaceuticals inc is a company based out of 324 s hyde park ave, tampa, fl, united states.